Novel combined single dose anti-hepatitis C therapy: a pilot study

The new anti-hepatitis C virus (HCV) molecules improve treatment regimens and outcomes, but there are drawbacks. New combinations should target the HCV infectious cycle and be effective against all HCV genotypes. We developed the novel formulation Catvira, composed of epigallocatechingallate (EGCG) ...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiha, Gamal, Soliman, Reham, Elbasiony, Mohamed, Darwish, Noureldien H. E., Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907074/
https://www.ncbi.nlm.nih.gov/pubmed/33633233
http://dx.doi.org/10.1038/s41598-021-84066-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907074/
https://www.ncbi.nlm.nih.gov/pubmed/33633233
http://dx.doi.org/10.1038/s41598-021-84066-3

Ejemplares similares